Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody
- PMID: 6125812
- DOI: 10.1016/s0140-6736(82)90923-0
Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody
Abstract
The usefulness of antibodies directed against tumour products for localisation and therapy of cancer is limited by the large proportion of administered antibody which remains non-specifically in the circulation and extravascular space. Liposomally entrapped second antibody (LESA) directed against the first (antitumour) antibody has been used to accelerate clearance of non-tumour-bound first antibody without affecting its clearance from the tumour. Intravenously administered LESA binds the first antibody and LESA is cleared by the reticuloendothelial system. LESA accelerated clearance of radiolabelled antibody directed against carcinoembryonic antigen (CEA) from the circulation in four of five patients with gastrointestinal cancer, enhancing gamma-camera imaging of the tumour in three of them. These results suggest that LESA can improve the sensitivity and specificity of tumour imaging with radiolabelled antitumour antibody. This strategy may also have the potential to improve the therapeutic ratio of some toxic agents linked to antitumour antibody.
Similar articles
-
Second antibody for improvement of antibody imaging: liposome-entrapped and free preparations in animal and human studies.Clin Exp Immunol. 1989 Nov;78(2):307-13. Clin Exp Immunol. 1989. PMID: 12412766 Free PMC article.
-
Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.Br J Cancer. 1989 Sep;60(3):406-12. doi: 10.1038/bjc.1989.295. Br J Cancer. 1989. PMID: 2789951 Free PMC article.
-
Improved radioimmunodetection of tumours using liposome-entrapped antibody.Biochim Biophys Acta. 1983 Apr 5;762(2):154-64. doi: 10.1016/0167-4889(83)90067-8. Biochim Biophys Acta. 1983. PMID: 6830870
-
Taking engineered anti-CEA antibodies to the clinic.J Immunol Methods. 1999 Dec 10;231(1-2):261-73. doi: 10.1016/s0022-1759(99)00162-3. J Immunol Methods. 1999. PMID: 10648943 Review.
-
Anti-antibody enhancement of tumor imaging.Cancer Treat Res. 1990;51:433-55. doi: 10.1007/978-1-4613-1497-4_22. Cancer Treat Res. 1990. PMID: 1977459 Review. No abstract available.
Cited by
-
Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.Br J Cancer. 1994 Mar;69(3):502-7. doi: 10.1038/bjc.1994.91. Br J Cancer. 1994. PMID: 8123481 Free PMC article.
-
Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins.Eur J Nucl Med. 1984;9(5):209-15. doi: 10.1007/BF00448541. Eur J Nucl Med. 1984. PMID: 6428891
-
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.Semin Nucl Med. 2010 May;40(3):190-203. doi: 10.1053/j.semnuclmed.2009.12.002. Semin Nucl Med. 2010. PMID: 20350628 Free PMC article. Review.
-
Intratumour factors influencing the access of antibody to tumour cells.Cancer Immunol Immunother. 1989;28(4):235-40. doi: 10.1007/BF00205231. Cancer Immunol Immunother. 1989. PMID: 2649244 Free PMC article. Review.
-
The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites.Br J Cancer. 1989 Sep;60(3):275-81. doi: 10.1038/bjc.1989.270. Br J Cancer. 1989. PMID: 2675955 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources